Pfizer: Number of Employees 2012-2025 | PFE
Interactive chart of Pfizer (PFE) annual worldwide employee count from 2012 to 2025.
- Pfizer total number of employees in 2024 was 81,000, a 7.95% decline from 2023.
- Pfizer total number of employees in 2023 was 88,000, a 6.02% increase from 2022.
- Pfizer total number of employees in 2022 was 83,000, a 5.06% increase from 2021.
- Pfizer total number of employees in 2021 was 79,000, a 0.64% increase from 2020.
| Pfizer Annual Employee Count | |
|---|---|
| 2024 | 81,000 |
| 2023 | 88,000 |
| 2022 | 83,000 |
| 2021 | 79,000 |
| 2020 | 78,500 |
| 2019 | 88,300 |
| 2018 | 92,400 |
| 2017 | 90,200 |
| 2016 | 96,500 |
| 2015 | 97,900 |
| 2014 | 78,300 |
| 2013 | 77,700 |
| 2012 | 91,500 |
| 2011 | 103,700 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $156.812B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Sanofi (SNY) | France | $112.219B | 10.39 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |